These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 37914510

  • 1. Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications.
    Kandzari DE, Townsend RR, Kario K, Mahfoud F, Weber MA, Schmieder RE, Pocock S, Tsioufis K, Konstantinidis D, Choi J, East C, Lauder L, Cohen DL, Kobayashi T, Schmid A, Lee DP, Ma A, Weil J, Agdirlioglu T, Schlaich MP, Shetty S, Devireddy CM, Lea J, Aoki J, Sharp ASP, Anderson R, Fahy M, DeBruin V, Brar S, Böhm M, SPYRAL HTN-ON MED Investigators.
    J Am Coll Cardiol; 2023 Nov 07; 82(19):1809-1823. PubMed ID: 37914510
    [Abstract] [Full Text] [Related]

  • 2. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial.
    Mahfoud F, Kandzari DE, Kario K, Townsend RR, Weber MA, Schmieder RE, Tsioufis K, Pocock S, Dimitriadis K, Choi JW, East C, D'Souza R, Sharp ASP, Ewen S, Walton A, Hopper I, Brar S, McKenna P, Fahy M, Böhm M.
    Lancet; 2022 Apr 09; 399(10333):1401-1410. PubMed ID: 35390320
    [Abstract] [Full Text] [Related]

  • 3. Impact of Antihypertensive Medication Changes After Renal Denervation Among Different Patient Groups: SPYRAL HTN-ON MED.
    Townsend RR, Ferdinand KC, Kandzari DE, Kario K, Mahfoud F, Weber MA, Schmieder RE, Pocock S, Tsioufis K, David S, Steigerwalt S, Walton A, Hopper I, Bertolet B, Sharif F, Fengler K, Fahy M, Hettrick DA, Brar S, Böhm M.
    Hypertension; 2024 May 09; 81(5):1095-1105. PubMed ID: 38314554
    [Abstract] [Full Text] [Related]

  • 4. Effect of Alcohol-Mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Medications: Primary Results From the TARGET BP I Randomized Clinical Trial.
    Kandzari DE, Weber MA, Pathak A, Zidar JP, Saxena M, David SW, Schmieder RE, Janas AJ, Langer C, Persu A, Mendelsohn FO, Ameloot K, Foster M, Fischell TA, Parise H, Mahfoud F.
    Circulation; 2024 Jun 11; 149(24):1875-1884. PubMed ID: 38587557
    [Abstract] [Full Text] [Related]

  • 5. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial.
    Bhatt DL, Vaduganathan M, Kandzari DE, Leon MB, Rocha-Singh K, Townsend RR, Katzen BT, Oparil S, Brar S, DeBruin V, Fahy M, Bakris GL, SYMPLICITY HTN-3 Steering Committee Investigators.
    Lancet; 2022 Oct 22; 400(10361):1405-1416. PubMed ID: 36130612
    [Abstract] [Full Text] [Related]

  • 6. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial.
    Kandzari DE, Böhm M, Mahfoud F, Townsend RR, Weber MA, Pocock S, Tsioufis K, Tousoulis D, Choi JW, East C, Brar S, Cohen SA, Fahy M, Pilcher G, Kario K, SPYRAL HTN-ON MED Trial Investigators.
    Lancet; 2018 Jun 09; 391(10137):2346-2355. PubMed ID: 29803589
    [Abstract] [Full Text] [Related]

  • 7. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial.
    Townsend RR, Mahfoud F, Kandzari DE, Kario K, Pocock S, Weber MA, Ewen S, Tsioufis K, Tousoulis D, Sharp ASP, Watkinson AF, Schmieder RE, Schmid A, Choi JW, East C, Walton A, Hopper I, Cohen DL, Wilensky R, Lee DP, Ma A, Devireddy CM, Lea JP, Lurz PC, Fengler K, Davies J, Chapman N, Cohen SA, DeBruin V, Fahy M, Jones DE, Rothman M, Böhm M, SPYRAL HTN-OFF MED trial investigators*.
    Lancet; 2017 Nov 11; 390(10108):2160-2170. PubMed ID: 28859944
    [Abstract] [Full Text] [Related]

  • 8. Effect of Heart Rate on the Outcome of Renal Denervation in Patients With Uncontrolled Hypertension.
    Böhm M, Tsioufis K, Kandzari DE, Kario K, Weber MA, Schmieder RE, Townsend RR, Kulenthiran S, Ukena C, Pocock S, Ewen S, Weil J, Fahy M, Mahfoud F.
    J Am Coll Cardiol; 2021 Sep 07; 78(10):1028-1038. PubMed ID: 34474735
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial.
    Böhm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE, Tsioufis K, Pocock S, Konstantinidis D, Choi JW, East C, Lee DP, Ma A, Ewen S, Cohen DL, Wilensky R, Devireddy CM, Lea J, Schmid A, Weil J, Agdirlioglu T, Reedus D, Jefferson BK, Reyes D, D'Souza R, Sharp ASP, Sharif F, Fahy M, DeBruin V, Cohen SA, Brar S, Townsend RR, SPYRAL HTN-OFF MED Pivotal Investigators.
    Lancet; 2020 May 02; 395(10234):1444-1451. PubMed ID: 32234534
    [Abstract] [Full Text] [Related]

  • 10. Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design.
    Böhm M, Townsend RR, Kario K, Kandzari D, Mahfoud F, Weber MA, Schmieder RE, Tsioufis K, Hickey GL, Fahy M, DeBruin V, Brar S, Pocock S.
    Clin Res Cardiol; 2020 Mar 02; 109(3):289-302. PubMed ID: 32034481
    [Abstract] [Full Text] [Related]

  • 11. Long-term reduction in morning and nighttime blood pressure after renal denervation: 36-month results from SPYRAL HTN-ON MED trial.
    Kario K, Mahfoud F, Kandzari DE, Townsend RR, Weber MA, Schmieder RE, Tsioufis K, Pocock S, Brar S, Hettrick DA, Fahy M, Böhm M.
    Hypertens Res; 2023 Jan 02; 46(1):280-288. PubMed ID: 36241705
    [Abstract] [Full Text] [Related]

  • 12. 12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal Denervation.
    Azizi M, Daemen J, Lobo MD, Mahfoud F, Sharp ASP, Schmieder RE, Wang Y, Saxena M, Lurz P, Sayer J, Bloch MJ, Basile J, Weber MA, Rump LC, Levy T, Sapoval M, Sanghvi K, Rader F, Fisher NDL, Gosse P, Abraham J, Claude L, Barman NC, McClure CK, Liu Y, Kirtane AJ, RADIANCE-HTN Investigators.
    JACC Cardiovasc Interv; 2020 Dec 28; 13(24):2922-2933. PubMed ID: 33357531
    [Abstract] [Full Text] [Related]

  • 13. Alcohol-mediated renal denervation in patients with hypertension in the absence of antihypertensive medications.
    Pathak A, Rudolph UM, Saxena M, Zeller T, Müller-Ehmsen J, Lipsic E, Schmieder RE, Sievert H, Halbach M, Sharif F, Parise H, Fischell TA, Weber MA, Kandzari DE, Mahfoud F.
    EuroIntervention; 2023 Sep 18; 19(7):602-611. PubMed ID: 37427416
    [Abstract] [Full Text] [Related]

  • 14. Effects of Renal Denervation vs Sham in Resistant Hypertension After Medication Escalation: Prespecified Analysis at 6 Months of the RADIANCE-HTN TRIO Randomized Clinical Trial.
    Azizi M, Mahfoud F, Weber MA, Sharp ASP, Schmieder RE, Lurz P, Lobo MD, Fisher NDL, Daemen J, Bloch MJ, Basile J, Sanghvi K, Saxena M, Gosse P, Jenkins JS, Levy T, Persu A, Kably B, Claude L, Reeve-Stoffer H, McClure C, Kirtane AJ, RADIANCE-HTN Investigators.
    JAMA Cardiol; 2022 Dec 01; 7(12):1244-1252. PubMed ID: 36350593
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and Safety of Catheter-Based Radiofrequency Renal Denervation in Chinese Patients With Uncontrolled Hypertension: The Randomized, Sham-Controlled, Multi-Center Iberis-HTN Trial.
    Jiang X, Mahfoud F, Li W, Dong H, Yu J, Yu S, Chen X, Wang P, Li Z, Lauder L, Wang Z, Ji Z, Dong Y, Han B, Zhu Z, Chen Y, Xu J, Zhao X, Fan W, Xie W, Hubbard B, Hu X, Kario K, Gao R.
    Circulation; 2024 Nov 12; 150(20):1588-1598. PubMed ID: 39229700
    [Abstract] [Full Text] [Related]

  • 16. Renal Denervation for Treating Hypertension: Current Scientific and Clinical Evidence.
    Weber MA, Mahfoud F, Schmieder RE, Kandzari DE, Tsioufis KP, Townsend RR, Kario K, Böhm M, Sharp ASP, Davies JE, Osborn JW, Fink GD, Euler DE, Cohen DL, Schlaich MP, Esler MD.
    JACC Cardiovasc Interv; 2019 Jun 24; 12(12):1095-1105. PubMed ID: 31221299
    [Abstract] [Full Text] [Related]

  • 17. Outcomes Following Radiofrequency Renal Denervation According to Antihypertensive Medications: Subgroup Analysis of the Global SYMPLICITY Registry DEFINE.
    Mahfoud F, Mancia G, Schmieder RE, Ruilope L, Narkiewicz K, Schlaich M, Williams B, Ribichini F, Weil J, Almerri K, Sharif F, Lauder L, Wanten M, Fahy M, Böhm M.
    Hypertension; 2023 Aug 24; 80(8):1759-1770. PubMed ID: 37317866
    [Abstract] [Full Text] [Related]

  • 18. Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control After Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial.
    Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Lobo MD, Sharp ASP, Bloch MJ, Basile J, Wang Y, Saxena M, Lurz P, Rader F, Sayer J, Fisher NDL, Fouassier D, Barman NC, Reeve-Stoffer H, McClure C, Kirtane AJ, RADIANCE-HTN Investigators.
    Circulation; 2019 May 28; 139(22):2542-2553. PubMed ID: 30880441
    [Abstract] [Full Text] [Related]

  • 19. Randomized Trials of Renal Denervation for Uncontrolled Hypertension: An Updated Meta-Analysis.
    Mufarrih SH, Qureshi NQ, Khan MS, Kazimuddin M, Secemsky E, Bloch MJ, Giri J, Cohen D, Swaminathan RV, Feldman DN, Alaswad K, Kirtane A, Kandzari D, Aronow HD.
    J Am Heart Assoc; 2024 Aug 20; 13(16):e034910. PubMed ID: 39140334
    [Abstract] [Full Text] [Related]

  • 20. Endovascular Ultrasound Renal Denervation to Treat Hypertension: The RADIANCE II Randomized Clinical Trial.
    Azizi M, Saxena M, Wang Y, Jenkins JS, Devireddy C, Rader F, Fisher NDL, Schmieder RE, Mahfoud F, Lindsey J, Sanghvi K, Todoran TM, Pacella J, Flack J, Daemen J, Sharp ASP, Lurz P, Bloch MJ, Weber MA, Lobo MD, Basile J, Claude L, Reeve-Stoffer H, McClure CK, Kirtane AJ, RADIANCE II Investigators and Collaborators.
    JAMA; 2023 Feb 28; 329(8):651-661. PubMed ID: 36853250
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.